Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p

EU orphan designation number: EU/3/17/1872   
Active ingredient: Chimeric locked nucleic acid deoxynucleoside phosphorothioate-linked oligonucleotide inhibitor directed against microRNA-155-5p
Indication: Treatment of cutaneous T-cell lymphoma
Sponsor: Miragen Therapeutics Europe Ltd
Cannon Place, 78 Cannon Street, London, EC4N6AF, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
23/05/2017 Orphan designation EMA/OD/011/17 (2017)3605 of 22/05/2017
8/04/2019 Change of name and/or address of sponsor